Ultima Genomics said it doubled its installed base in 2025, reported a multi‑fold rise in consumables revenue and a contracted revenue backlog more than double 2025 revenue as it expands partnerships across oncology labs and NGS vendors. CEO commentary highlighted growing adoption for research and clinical projects and upcoming product news at AGBT. Element Biosciences announced plans to launch an IVDR version of its Aviti platform and previewed a new benchtop sequencer aimed at $100 genome economics and multiomics upgradability. Element said Aviti24 multiomics uptake is increasing among pharma customers and that the company will detail the new benchtop at a February event. Both updates signal commercial momentum in sequencing hardware and consumables: vendors are pushing throughput, cost reductions and clinical‑grade offerings to capture growing demand across diagnostics and discovery.